Coated medical devices for the treatment of vulnerable plaque
View Patent ↗Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. In addition to reducing or substantially eliminating a biological organism's reaction to the introduction of the medical device to the organism, the medical device in combination with one or more therapeutic drugs, agents and/or compounds may be utilized to treat various vascular diseases, for example, restenosis and vulnerable plaque. In the case of vulnerable plaque, one or more drugs, agents or compounds may be utilized to treat the various aspects of vulnerable plaque and these drugs, agents and/or compounds may be released with a given release profile for the most effective treatment. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned.
1. An intraluminal medical device for the treatment of atherosclerotic vulnerable plaque comprising:
a stent configured to provide structural support for a fibrous cap of a vulnerable plaque lesion;
a biocompatible vehicle affixed to at least a portion of the stent, the biocompatible vehicle including at least one layer in direct contact with the internal surface of a vessel in which the stent is positioned;
at least one first agent in a therapeutic dosage incorporated into the biocompatible vehicle for treating the inflammation associated with the acute phase of the vulnerable plaque lesion;
at least one second agent in a therapeutic dosage incorporated into the biocompatible vehicle for treating the lipid core associated with the chronic phase of the vulnerable plaque lesion, the biocompatible vehicle being configured to release the at least one first agent faster than the at least one second agent and configured to release the at least one first agent for a shorter duration than the at least one second agent; at least one third agent in a therapeutic dosage incorporated into the biocompatible vehicle for preventing neointimal hyperplasia caused by the placement of the stent.
2. The intraluminal medical device for the treatment of atherosclerotic vulnerable plaque according to claim 1 , wherein the stent is balloon expandable.
3. The intraluminal medical device for the treatment of atherosclerotic vulnerable plaque according to claim 1 , wherein the stent is self-expanding.
4. The intraluminal medical device for the treatment of atherosclerotic vulnerable plaque according to claim 1 , wherein the biocompatible vehicle comprises a polymeric coating.
5. The intraluminal medical device for the treatment of atherosclerotic vulnerable plaque according to claim 4 , wherein the polymeric coating comprises at least one layer configured to release the at least one first agent faster than the at least one second agent and to release the at least one first agent for a shorter duration than the at least one second agent.
6. The intraluminal medical device for the treatment of atherosclerotic vulnerable plaque according to claim 5 , wherein the at least one first agent comprises an anti-inflammatory/inflammation blocking agent.
7. The intraluminal medical device, for the treatment of atherosclerotic vulnerable plaque according to claim 5 , wherein the at least one first agent comprises an anti-proliferative agent.
8. The intraluminal medical device for the treatment of atherosclerotic vulnerable plaque according to claim 5 , wherein the at least one first agent comprises an anti-thrombogenic agent.
9. The intraluminal medical device for the treatment of atherosclerotic vulnerable plaque according to claim 5 , wherein the at least one first agent comprises rapamycin.
10. The intraluminal medical device for the treatment of atherosclerotic vulnerable plaque according to claim 5 , wherein the at least one first agent comprises dexamethasone.
11. The intraluminal medical device for the treatment of atherosclerotic vulnerable plaque according to claim 5 , wherein the at least one first agent comprises anti-inflammatory corticosteroids.
12. The intraluminal medical device for the treatment of atherosclerotic vulnerable plaque according to claim 5 , wherein the at least one first agent comprises rapamycin derivatives.
13. The intraluminal medical device for the treatment of atherosclerotic vulnerable plaque according to claim 5 wherein the at least one first agent comprises rapamycin analogs.
14. The intraluminal medical device for the treatment of atherosclerotic vulnerable plaque according to claim 5 wherein the at least one first agent comprises a direct inhibitor of the target of rapamycin kinase (mTOR).
15. The intraluminal medical device for the treatment of atherosclerotic vulnerable plaque according to claim 5 wherein the at least one first agent comprises a taxane, including paclitaxel and a taxane derivative that inhibits microtubule function.
16. The intraluminal medical device for the treatment of atherosclerotic vulnerable plaque according to claim 5 wherein the at least one first agent comprises a cyclin dependent kinase inhibitor that will block the cell cycle.
17. The intraluminal medical device for the treatment of atherosclerotic vulnerable plaque according to claim 5 wherein the at least one first agent comprises a retinoid.
18. The intraluminal medical device for the treatment of atherosclerotic vulnerable plaque according to claim 5 wherein the at least one first agent comprises a growth factor receptor kinase inhibitor.
19. The intraluminal medical device for the treatment of atherosclerotic vulnerable plaque according to claim 5 wherein the at least one first agent comprises a famesyl transferase inhibitor.
20. The intraluminal medical device for the treatment of atherosclerotic vulnerable plaque according to claim 5 wherein the at least one first agent comprises a P 38 MAP kinase inhibitor.
21. The intraluminal medical device for the treatment of atherosclerotic vulnerable plaque according to claim 5 wherein the at least one first agent comprises an antagonist of tumor necrosis factor.
22. The intraluminal medical device for the treatment of atherosclerotic vulnerable plaque according to claim 5 wherein the at least one first agent comprises a mast cell stabilizer.
23. The intraluminal medical device for the treatment of atherosclerotic vulnerable plaque according to claim 5 wherein the at least one first agent comprises an antioxidant.
24. The intraluminal medical device for the treatment of atherosclerotic vulnerable plaque according to claim 5 , wherein the at least one second agent comprises a lipid lowering agent.
25. The intraluminal medical device for the treatment of atherosclerotic vulnerable plaque according to claim 24 , wherein the lipid lowering agent is an HMG co-enzyme reductase inhibitor or statin.
26. The intraluminal medical device for the treatment of atherosclerotic vulnerable plaque according to claim 24 , wherein the lipid lowering agent comprises rapamycin.
27. The intraluminal medical device for the treatment of atherosclerotic vulnerable plaque according to claim 5 , wherein the at least one second agent comprises a protease inhibitor including a matrix metalloprotease inhibitor.
28. The intraluminal medical device for the treatment of atherosclerotic vulnerable plaque according to claim 5 , wherein the at least one second agent comprises an antiapoptotic agent.
29. The intraluminal medical device for the treatment of atherosclerotic vulnerable plaque according to claim 5 , wherein the at least one second agent comprises a TGFbeta agonist.
30. The intraluminal medical device for the treatment of atherosclerotic vulnerable plaque according to claim 5 , wherein the at least one second agent comprises a vitronectin antagonist.